2V2X - JenaLib

Asymmetric Unit (24, 48)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
01	UniProt	VAR_004334	F	33	Y	1A02_HUMAN	Polymorphism	2075684	A/D	F	9	Y
02	UniProt	VAR_004335	D	54	N	1A02_HUMAN	Polymorphism	41549215	A/D	D	30	N
03	UniProt	VAR_016726	A	65	G	1A02_HUMAN	Polymorphism	41557613	A/D	A	41	G
04	UniProt	VAR_004336	Q	67	R	1A02_HUMAN	Polymorphism	41559117	A/D	Q	43	R
05	UniProt	VAR_076446	R	89	G	1A02_HUMAN	Polymorphism	199474430	A/D	R	65	G
06	UniProt	VAR_004337	K	90	N	1A02_HUMAN	Polymorphism	199474436	A/D	K	66	N
07	UniProt	VAR_016727	H	94	Q	1A02_HUMAN	Polymorphism	78306866	A/D	H	70	Q
08	UniProt	VAR_004338	T	97	I	1A02_HUMAN	Polymorphism	199474457	A/D	T	73	I
09	UniProt	VAR_016728	H	98	D	1A02_HUMAN	Polymorphism	1136683	A/D	H	74	D
10	UniProt	VAR_076691	D	96	N	B2MG_HUMAN	Disease (AMYL8)	398122820	B/E	D	76	N
11	UniProt	VAR_004339	V	119	L	1A02_HUMAN	Polymorphism	1071743	A/D	V	95	L
12	UniProt	VAR_004340	R	121	M	1A02_HUMAN	Polymorphism	199474485	A/D	R	97	M
13	UniProt	VAR_004341	Y	123	C	1A02_HUMAN	Polymorphism	1136697	A/D	Y	99	C
14	UniProt	VAR_004342	Y	123	F	1A02_HUMAN	Polymorphism	1136697	A/D	Y	99	F
15	UniProt	VAR_004343	W	131	G	1A02_HUMAN	Polymorphism	1136702	A/D	W	107	G
16	UniProt	VAR_004344	M	162	K	1A02_HUMAN	Polymorphism	41549316	A/D	M	138	K
17	UniProt	VAR_004345	A	173	T	1A02_HUMAN	Polymorphism	1059526	A/D	A	149	T
18	UniProt	VAR_004346	V	176	E	1A02_HUMAN	Polymorphism	9256983	A/D	V	152	E
19	UniProt	VAR_004348	L	180	Q	1A02_HUMAN	Polymorphism	---	A/D	L	156	Q
20	UniProt	VAR_004347	L	180	W	1A02_HUMAN	Polymorphism	9260156	A/D	L	156	W
21	UniProt	VAR_004349	T	187	E	1A02_HUMAN	Polymorphism	---	A/D	T	163	E
22	UniProt	VAR_016729	E	190	D	1A02_HUMAN	Polymorphism	879577815	A/D	E	166	D
23	UniProt	VAR_016730	W	191	G	1A02_HUMAN	Polymorphism	3098019	A/D	W	167	G
24	UniProt	VAR_004350	A	260	E	1A02_HUMAN	Polymorphism	41540417	A/D	A	236	E

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

Biological Unit 1 (24, 24)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
01	UniProt	VAR_004334	F	33	Y	1A02_HUMAN	Polymorphism	2075684	A	F	9	Y
02	UniProt	VAR_004335	D	54	N	1A02_HUMAN	Polymorphism	41549215	A	D	30	N
03	UniProt	VAR_016726	A	65	G	1A02_HUMAN	Polymorphism	41557613	A	A	41	G
04	UniProt	VAR_004336	Q	67	R	1A02_HUMAN	Polymorphism	41559117	A	Q	43	R
05	UniProt	VAR_076446	R	89	G	1A02_HUMAN	Polymorphism	199474430	A	R	65	G
06	UniProt	VAR_004337	K	90	N	1A02_HUMAN	Polymorphism	199474436	A	K	66	N
07	UniProt	VAR_016727	H	94	Q	1A02_HUMAN	Polymorphism	78306866	A	H	70	Q
08	UniProt	VAR_004338	T	97	I	1A02_HUMAN	Polymorphism	199474457	A	T	73	I
09	UniProt	VAR_016728	H	98	D	1A02_HUMAN	Polymorphism	1136683	A	H	74	D
10	UniProt	VAR_076691	D	96	N	B2MG_HUMAN	Disease (AMYL8)	398122820	B	D	76	N
11	UniProt	VAR_004339	V	119	L	1A02_HUMAN	Polymorphism	1071743	A	V	95	L
12	UniProt	VAR_004340	R	121	M	1A02_HUMAN	Polymorphism	199474485	A	R	97	M
13	UniProt	VAR_004341	Y	123	C	1A02_HUMAN	Polymorphism	1136697	A	Y	99	C
14	UniProt	VAR_004342	Y	123	F	1A02_HUMAN	Polymorphism	1136697	A	Y	99	F
15	UniProt	VAR_004343	W	131	G	1A02_HUMAN	Polymorphism	1136702	A	W	107	G
16	UniProt	VAR_004344	M	162	K	1A02_HUMAN	Polymorphism	41549316	A	M	138	K
17	UniProt	VAR_004345	A	173	T	1A02_HUMAN	Polymorphism	1059526	A	A	149	T
18	UniProt	VAR_004346	V	176	E	1A02_HUMAN	Polymorphism	9256983	A	V	152	E
19	UniProt	VAR_004348	L	180	Q	1A02_HUMAN	Polymorphism	---	A	L	156	Q
20	UniProt	VAR_004347	L	180	W	1A02_HUMAN	Polymorphism	9260156	A	L	156	W
21	UniProt	VAR_004349	T	187	E	1A02_HUMAN	Polymorphism	---	A	T	163	E
22	UniProt	VAR_016729	E	190	D	1A02_HUMAN	Polymorphism	879577815	A	E	166	D
23	UniProt	VAR_016730	W	191	G	1A02_HUMAN	Polymorphism	3098019	A	W	167	G
24	UniProt	VAR_004350	A	260	E	1A02_HUMAN	Polymorphism	41540417	A	A	236	E

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

Biological Unit 2 (24, 24)

								dbSNP	PDB
No.	Source	Variant ID	Variant			UniProt ID	Status	ID	Chain	Variant
01	UniProt	VAR_004334	F	33	Y	1A02_HUMAN	Polymorphism	2075684	D	F	9	Y
02	UniProt	VAR_004335	D	54	N	1A02_HUMAN	Polymorphism	41549215	D	D	30	N
03	UniProt	VAR_016726	A	65	G	1A02_HUMAN	Polymorphism	41557613	D	A	41	G
04	UniProt	VAR_004336	Q	67	R	1A02_HUMAN	Polymorphism	41559117	D	Q	43	R
05	UniProt	VAR_076446	R	89	G	1A02_HUMAN	Polymorphism	199474430	D	R	65	G
06	UniProt	VAR_004337	K	90	N	1A02_HUMAN	Polymorphism	199474436	D	K	66	N
07	UniProt	VAR_016727	H	94	Q	1A02_HUMAN	Polymorphism	78306866	D	H	70	Q
08	UniProt	VAR_004338	T	97	I	1A02_HUMAN	Polymorphism	199474457	D	T	73	I
09	UniProt	VAR_016728	H	98	D	1A02_HUMAN	Polymorphism	1136683	D	H	74	D
10	UniProt	VAR_076691	D	96	N	B2MG_HUMAN	Disease (AMYL8)	398122820	E	D	76	N
11	UniProt	VAR_004339	V	119	L	1A02_HUMAN	Polymorphism	1071743	D	V	95	L
12	UniProt	VAR_004340	R	121	M	1A02_HUMAN	Polymorphism	199474485	D	R	97	M
13	UniProt	VAR_004341	Y	123	C	1A02_HUMAN	Polymorphism	1136697	D	Y	99	C
14	UniProt	VAR_004342	Y	123	F	1A02_HUMAN	Polymorphism	1136697	D	Y	99	F
15	UniProt	VAR_004343	W	131	G	1A02_HUMAN	Polymorphism	1136702	D	W	107	G
16	UniProt	VAR_004344	M	162	K	1A02_HUMAN	Polymorphism	41549316	D	M	138	K
17	UniProt	VAR_004345	A	173	T	1A02_HUMAN	Polymorphism	1059526	D	A	149	T
18	UniProt	VAR_004346	V	176	E	1A02_HUMAN	Polymorphism	9256983	D	V	152	E
19	UniProt	VAR_004348	L	180	Q	1A02_HUMAN	Polymorphism	---	D	L	156	Q
20	UniProt	VAR_004347	L	180	W	1A02_HUMAN	Polymorphism	9260156	D	L	156	W
21	UniProt	VAR_004349	T	187	E	1A02_HUMAN	Polymorphism	---	D	T	163	E
22	UniProt	VAR_016729	E	190	D	1A02_HUMAN	Polymorphism	879577815	D	E	166	D
23	UniProt	VAR_016730	W	191	G	1A02_HUMAN	Polymorphism	3098019	D	W	167	G
24	UniProt	VAR_004350	A	260	E	1A02_HUMAN	Polymorphism	41540417	D	A	236	E

SNP/SAP Summary Statistics (UniProtKB/Swiss-Prot)

PROSITE Motifs (1, 4)

Exons (0, 0)

Sequences/Alignments

Asymmetric Unit

Reformat:	Number of residues per line = ('0' or empty: single-line sequence representation)
	Number of residues per labelling interval =
	UniProt sequence: complete aligned part

Show mapping:	SCOP domains	CATH domains	Pfam domains	Secondary structure (by author)
	SAPs(SNPs)	PROSITE motifs	Exons
	(details for a mapped element are shown in a popup box when the mouse pointer rests over it)

Chain A from PDB  Type:PROTEIN  Length:276
 aligned with 1A02_HUMAN | P01892 from UniProtKB/Swiss-Prot  Length:365

    Alignment length:276
                                    34        44        54        64        74        84        94       104       114       124       134       144       154       164       174       184       194       204       214       224       234       244       254       264       274       284       294      
           1A02_HUMAN    25 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEP 300
               SCOP domains d2v2xa2 A:1-181 Class I MHC, alpha-1 and alpha-2 domains                                                                                                                             d2v2xa1 A:182-276 Class I MHC, alpha-3 domain                                                   SCOP domains
               CATH domains 2v2xA01 A:1-181 Murine Class I Major Histocompatibility Complex, H2-DB, subunit A, domain 1                                                                                          2v2xA02 A:182-270 Immunoglobulins                                                        ------ CATH domains
               Pfam domains ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Pfam domains
         Sec.struct. author ..eeeeeeeeee........eeeeeeee..eeeeeee........ee.hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh........eeeeeeeeee.....eeeeeeeeee..eeeeee......eee.hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh.....eeeeeeee....eeeeeeeeeee.....eeeeee..ee.hhhhee...ee.....eeeeeeeeee..hhh.eeeeee.......eee.... Sec.struct. author
             SAPs(SNPs) (1) --------Y--------------------N----------G-R---------------------GN---Q--ID--------------------L-M-C-------G------------------------------K----------T--E---Q------E--DG--------------------------------------------------------------------E---------------------------------------- SAPs(SNPs) (1)
             SAPs(SNPs) (2) --------------------------------------------------------------------------------------------------F--------------------------------------------------------W------------------------------------------------------------------------------------------------------------------------ SAPs(SNPs) (2)
                    PROSITE ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------IG_MHC ------------- PROSITE
                 Transcript ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Transcript
                 2v2x A   1 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEP 276
                                    10        20        30        40        50        60        70        80        90       100       110       120       130       140       150       160       170       180       190       200       210       220       230       240       250       260       270

Chain B from PDB  Type:PROTEIN  Length:100
 aligned with B2MG_HUMAN | P61769 from UniProtKB/Swiss-Prot  Length:119

    Alignment length:100
                                    29        39        49        59        69        79        89        99       109       119
           B2MG_HUMAN    20 AIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM 119
               SCOP domains d2v2xb_ B: beta2-microglobulin                                                                       SCOP domains
               CATH domains 2v2xB00 B:0-99 Immunoglobulins                                                                       CATH domains
               Pfam domains ---------------------------------------------------------------------------------------------------- Pfam domains
         Sec.struct. author ......eeeeee.........eeeeeeeeee.....eeeeee..ee....ee...ee.....eeeeeeeee.......eeeeee.......eeee..... Sec.struct. author
                 SAPs(SNPs) ----------------------------------------------------------------------------N----------------------- SAPs(SNPs)
                    PROSITE ------------------------------------------------------------------------------IG_MHC --------------- PROSITE
                 Transcript ---------------------------------------------------------------------------------------------------- Transcript
                 2v2x B   0 MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM  99
                                     9        19        29        39        49        59        69        79        89        99

Chain C from PDB  Type:PROTEIN  Length:9
                                         
               SCOP domains --------- SCOP domains
               CATH domains --------- CATH domains
               Pfam domains --------- Pfam domains
         Sec.struct. author ......... Sec.struct. author
                 SAPs(SNPs) --------- SAPs(SNPs)
                    PROSITE --------- PROSITE
                 Transcript --------- Transcript
                 2v2x C   1 SLFNTVATL   9

Chain D from PDB  Type:PROTEIN  Length:276
 aligned with 1A02_HUMAN | P01892 from UniProtKB/Swiss-Prot  Length:365

    Alignment length:276
                                    34        44        54        64        74        84        94       104       114       124       134       144       154       164       174       184       194       204       214       224       234       244       254       264       274       284       294      
           1A02_HUMAN    25 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEP 300
               SCOP domains d2v2xd2 D:1-181 Class I MHC, alpha-1 and alpha-2 domains                                                                                                                             d2v2xd1 D:182-276 Class I MHC, alpha-3 domain                                                   SCOP domains
               CATH domains 2v2xD01 D:1-181 Murine Class I Major Histocompatibility Complex, H2-DB, subunit A, domain 1                                                                                          2v2xD02 D:182-270 Immunoglobulins                                                        ------ CATH domains
           Pfam domains (1) MHC_I-2v2xD03 D:1-179                                                                                                                                                              --------C1-set-2v2xD01 D:188-271                                                            ----- Pfam domains (1)
           Pfam domains (2) MHC_I-2v2xD04 D:1-179                                                                                                                                                              --------C1-set-2v2xD02 D:188-271                                                            ----- Pfam domains (2)
         Sec.struct. author ..eeeeeeeeee........eeeeeeee..eeeeeee........ee.hhhhh..hhhhhhhhhhhhhhhhhhhhhhhhhhhhhh........eeeeeeeeee.....eeeeeeeeee..eeeeee......eee.hhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhhh.....eeeeeeee....eeeeeeeeeee.....eeeeee..ee.hhhhee...ee.....eeeeeeeeee..hhh.eeeeee.......eeee... Sec.struct. author
             SAPs(SNPs) (1) --------Y--------------------N----------G-R---------------------GN---Q--ID--------------------L-M-C-------G------------------------------K----------T--E---Q------E--DG--------------------------------------------------------------------E---------------------------------------- SAPs(SNPs) (1)
             SAPs(SNPs) (2) --------------------------------------------------------------------------------------------------F--------------------------------------------------------W------------------------------------------------------------------------------------------------------------------------ SAPs(SNPs) (2)
                    PROSITE ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------IG_MHC ------------- PROSITE
                 Transcript ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ Transcript
                 2v2x D   1 GSHSMRYFFTSVSRPGRGEPRFIAVGYVDDTQFVRFDSDAASQRMEPRAPWIEQEGPEYWDGETRKVKAHSQTHRVDLGTLRGYYNQSEAGSHTVQRMYGCDVGSDWRFLRGYHQYAYDGKDYIALKEDLRSWTAADMAAQTTKHKWEAAHVAEQLRAYLEGTCVEWLRRYLENGKETLQRTDAPKTHMTHHAVSDHEATLRCWALSFYPAEITLTWQRDGEDQTQDTELVETRPAGDGTFQKWAAVVVPSGQEQRYTCHVQHEGLPKPLTLRWEP 276
                                    10        20        30        40        50        60        70        80        90       100       110       120       130       140       150       160       170       180       190       200       210       220       230       240       250       260       270

Chain E from PDB  Type:PROTEIN  Length:100
 aligned with B2MG_HUMAN | P61769 from UniProtKB/Swiss-Prot  Length:119

    Alignment length:100
                                    29        39        49        59        69        79        89        99       109       119
           B2MG_HUMAN    20 AIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM 119
               SCOP domains d2v2xe_ E: beta2-microglobulin                                                                       SCOP domains
               CATH domains 2v2xE00 E:0-99 Immunoglobulins                                                                       CATH domains
           Pfam domains (1) -----------C1-set-2v2xE01 E:11-92                                                            ------- Pfam domains (1)
           Pfam domains (2) -----------C1-set-2v2xE02 E:11-92                                                            ------- Pfam domains (2)
         Sec.struct. author ......eeeeee.........eeeeeeeeee.....eeeeee..ee....ee...ee.....eeeeeeeee.......eeeeee.......eeee..... Sec.struct. author
                 SAPs(SNPs) ----------------------------------------------------------------------------N----------------------- SAPs(SNPs)
                    PROSITE ------------------------------------------------------------------------------IG_MHC --------------- PROSITE
                 Transcript ---------------------------------------------------------------------------------------------------- Transcript
                 2v2x E   0 MIQRTPKIQVYSRHPAENGKSNFLNCYVSGFHPSDIEVDLLKNGERIEKVEHSDLSFSKDWSFYLLYYTEFTPTEKDEYACRVNHVTLSQPKIVKWDRDM  99
                                     9        19        29        39        49        59        69        79        89        99

Chain F from PDB  Type:PROTEIN  Length:9
                                         
               SCOP domains --------- SCOP domains
               CATH domains --------- CATH domains
               Pfam domains --------- Pfam domains
         Sec.struct. author ......... Sec.struct. author
                 SAPs(SNPs) --------- SAPs(SNPs)
                    PROSITE --------- PROSITE
                 Transcript --------- Transcript
                 2v2x F   1 SLFNTVATL   9

Legend:		→ Mismatch	(orange background)
	-	→ Gap	(green background, '-', border residues have a numbering label)
		→ Modified Residue	(blue background, lower-case, 'x' indicates undefined single-letter code, labelled with number + name)
	x	→ Chemical Group	(purple background, 'x', labelled with number + name, e.g. ACE or NH2)
	extra numbering lines below/above indicate numbering irregularities and modified residue names etc., number ends below/above '\|'

Classification and Annotation

SCOP Domains (3, 6)

CATH Domains (2, 6)

Pfam Domains (2, 6)

Gene Ontology (72, 94)

Asymmetric Unit(hide GO term definitions)

Chain A,D (1A02_HUMAN | P01892)

molecular function
	GO:0042608	T cell receptor binding	Interacting selectively and non-covalently with a T cell receptor, the antigen-recognizing receptor on the surface of T cells.
	GO:0046977	TAP binding	Interacting selectively and non-covalently with TAP protein, transporter associated with antigen processing protein. TAP protein is a heterodimeric peptide transporter consisting of the subunits TAP1 and TAP2.
	GO:0030881	beta-2-microglobulin binding	Interacting selectively and non-covalently with beta-2-microglobulin.
	GO:0042605	peptide antigen binding	Interacting selectively and non-covalently with an antigen peptide.
	GO:0005515	protein binding	Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
	GO:0005102	receptor binding	Interacting selectively and non-covalently with one or more specific sites on a receptor molecule, a macromolecule that undergoes combination with a hormone, neurotransmitter, drug or intracellular messenger to initiate a change in cell function.
biological process
	GO:0019731	antibacterial humoral response	An immune response against bacteria mediated through a body fluid. Examples of this process are the antibacterial humoral responses in Mus musculus and Drosophila melanogaster.
	GO:0019882	antigen processing and presentation	The process in which an antigen-presenting cell expresses antigen (peptide or lipid) on its cell surface in association with an MHC protein complex.
	GO:0019885	antigen processing and presentation of endogenous peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex. The peptide antigen is typically, but not always, processed from a whole protein. Class I here refers to classical class I molecules.
	GO:0002486	antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent	The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP-independent ER pathway. The peptide is typically a fragment of a larger endogenous protein which has been degraded within the cell and becomes associated with the MHC class I molecule in the ER following transport from the cytosol via a TAP-independent pathway. Class I here refers to classical class I molecules.
	GO:0002479	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class I molecule. Class I here refers to classical class I molecules.
	GO:0002480	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class I here refers to classical class I molecules.
	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules.
	GO:0050830	defense response to Gram-positive bacterium	Reactions triggered in response to the presence of a Gram-positive bacterium that act to protect the cell or organism.
	GO:0006955	immune response	Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.
	GO:0002376	immune system process	Any process involved in the development or functioning of the immune system, an organismal system for calibrated responses to potential internal or invasive threats.
	GO:0060333	interferon-gamma-mediated signaling pathway	A series of molecular signals initiated by the binding of interferon-gamma to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Interferon gamma is the only member of the type II interferon found so far.
	GO:2001187	positive regulation of CD8-positive, alpha-beta T cell activation	Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell activation.
	GO:2000566	positive regulation of CD8-positive, alpha-beta T cell proliferation	Any process that activates or increases the frequency, rate or extent of CD8-positive, alpha-beta T cell proliferation.
	GO:0002726	positive regulation of T cell cytokine production	Any process that activates or increases the frequency, rate, or extent of T cell cytokine production.
	GO:0001916	positive regulation of T cell mediated cytotoxicity	Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity.
	GO:0032729	positive regulation of interferon-gamma production	Any process that activates or increases the frequency, rate, or extent of interferon-gamma production. Interferon-gamma is also known as type II interferon.
	GO:2000568	positive regulation of memory T cell activation	Any process that activates or increases the frequency, rate or extent of memory T cell activation.
	GO:0050690	regulation of defense response to virus by virus	Any viral process that modulates the frequency, rate, or extent of the antiviral response of the host cell or organism.
	GO:0050776	regulation of immune response	Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.
	GO:0060337	type I interferon signaling pathway	A series of molecular signals initiated by the binding of a type I interferon to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Type I interferons include the interferon-alpha, beta, delta, episilon, zeta, kappa, tau, and omega gene families.
	GO:0016032	viral process	A multi-organism process in which a virus is a participant. The other participant is the host. Includes infection of a host cell, replication of the viral genome, and assembly of progeny virus particles. In some cases the viral genetic material may integrate into the host genome and only subsequently, under particular circumstances, 'complete' its life cycle.
cellular component
	GO:0012507	ER to Golgi transport vesicle membrane	The lipid bilayer surrounding a vesicle transporting substances from the endoplasmic reticulum to the Golgi.
	GO:0005794	Golgi apparatus	A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions.
	GO:0005797	Golgi medial cisterna	The middle Golgi cisterna (or cisternae).
	GO:0000139	Golgi membrane	The lipid bilayer surrounding any of the compartments of the Golgi apparatus.
	GO:0042612	MHC class I protein complex	A transmembrane protein complex composed of a MHC class I alpha chain and an invariant beta2-microglobin chain, and with or without a bound peptide antigen. Class I here refers to classical class I molecules.
	GO:0009986	cell surface	The external part of the cell wall and/or plasma membrane.
	GO:0031901	early endosome membrane	The lipid bilayer surrounding an early endosome.
	GO:0005783	endoplasmic reticulum	The irregular network of unit membranes, visible only by electron microscopy, that occurs in the cytoplasm of many eukaryotic cells. The membranes form a complex meshwork of tubular channels, which are often expanded into slitlike cavities called cisternae. The ER takes two forms, rough (or granular), with ribosomes adhering to the outer surface, and smooth (with no ribosomes attached).
	GO:0070971	endoplasmic reticulum exit site	An endoplasmic reticulum part at which COPII-coated vesicles are produced.
	GO:0071556	integral component of lumenal side of endoplasmic reticulum membrane	The component of the endoplasmic reticulum membrane consisting of the gene products that penetrate only the lumenal side of the membrane.
	GO:0016021	integral component of membrane	The component of a membrane consisting of the gene products and protein complexes having at least some part of their peptide sequence embedded in the hydrophobic region of the membrane.
	GO:0016020	membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
	GO:0030670	phagocytic vesicle membrane	The lipid bilayer surrounding a phagocytic vesicle.
	GO:0005886	plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

Chain B,E (B2MG_HUMAN | P61769)

molecular function
	GO:0042802	identical protein binding	Interacting selectively and non-covalently with an identical protein or proteins.
	GO:0005515	protein binding	Interacting selectively and non-covalently with any protein or protein complex (a complex of two or more proteins that may include other nonprotein molecules).
biological process
	GO:0033077	T cell differentiation in thymus	The process in which a precursor cell type acquires the specialized features of a T cell via a differentiation pathway dependent upon transit through the thymus.
	GO:0019731	antibacterial humoral response	An immune response against bacteria mediated through a body fluid. Examples of this process are the antibacterial humoral responses in Mus musculus and Drosophila melanogaster.
	GO:0019885	antigen processing and presentation of endogenous peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen of endogenous origin on its cell surface in association with an MHC class I protein complex. The peptide antigen is typically, but not always, processed from a whole protein. Class I here refers to classical class I molecules.
	GO:0002479	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-dependent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class I molecule. Class I here refers to classical class I molecules.
	GO:0002480	antigen processing and presentation of exogenous peptide antigen via MHC class I, TAP-independent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class I protein complex following intracellular transport via a pathway not requiring TAP (transporter associated with antigen processing). The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell. Class I here refers to classical class I molecules.
	GO:0002481	antigen processing and presentation of exogenous protein antigen via MHC class Ib, TAP-dependent	The process in which an antigen-presenting cell expresses a peptide antigen of exogenous origin on its cell surface in association with an MHC class Ib protein complex following intracellular transport via a TAP (transporter associated with antigen processing) pathway. The peptide is typically a fragment of a larger exogenous protein which has been degraded within the cell and is dependent on TAP transport from the cytosol to ER for association with the MHC class Ib molecule. Class Ib here refers to non-classical class I molecules, such as those of the HLA-E gene family.
	GO:0002474	antigen processing and presentation of peptide antigen via MHC class I	The process in which an antigen-presenting cell expresses a peptide antigen on its cell surface in association with an MHC class I protein complex. Class I here refers to classical class I molecules.
	GO:0044267	cellular protein metabolic process	The chemical reactions and pathways involving a specific protein, rather than of proteins in general, occurring at the level of an individual cell. Includes cellular protein modification.
	GO:0071281	cellular response to iron ion	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of an iron ion stimulus.
	GO:0071222	cellular response to lipopolysaccharide	Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a lipopolysaccharide stimulus; lipopolysaccharide is a major component of the cell wall of gram-negative bacteria.
	GO:0050829	defense response to Gram-negative bacterium	Reactions triggered in response to the presence of a Gram-negative bacterium that act to protect the cell or organism.
	GO:0050830	defense response to Gram-positive bacterium	Reactions triggered in response to the presence of a Gram-positive bacterium that act to protect the cell or organism.
	GO:0006955	immune response	Any immune system process that functions in the calibrated response of an organism to a potential internal or invasive threat.
	GO:0002376	immune system process	Any process involved in the development or functioning of the immune system, an organismal system for calibrated responses to potential internal or invasive threats.
	GO:0045087	innate immune response	Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.
	GO:0060333	interferon-gamma-mediated signaling pathway	A series of molecular signals initiated by the binding of interferon-gamma to a receptor on the surface of a cell, and ending with regulation of a downstream cellular process, e.g. transcription. Interferon gamma is the only member of the type II interferon found so far.
	GO:0055072	iron ion homeostasis	Any process involved in the maintenance of an internal steady state of iron ions within an organism or cell.
	GO:0010977	negative regulation of neuron projection development	Any process that decreases the rate, frequency or extent of neuron projection development. Neuron projection development is the process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).
	GO:1900121	negative regulation of receptor binding	Any process that stops, prevents or reduces the frequency, rate or extent of a protein or other molecule binding to a receptor.
	GO:0002726	positive regulation of T cell cytokine production	Any process that activates or increases the frequency, rate, or extent of T cell cytokine production.
	GO:0001916	positive regulation of T cell mediated cytotoxicity	Any process that activates or increases the frequency, rate or extent of T cell mediated cytotoxicity.
	GO:1904434	positive regulation of ferrous iron binding	Any process that activates or increases the frequency, rate or extent of ferrous iron binding.
	GO:0032092	positive regulation of protein binding	Any process that activates or increases the frequency, rate or extent of protein binding.
	GO:1900122	positive regulation of receptor binding	Any process that activates or increases the frequency, rate or extent of a protein or other molecule binding to a receptor.
	GO:0048260	positive regulation of receptor-mediated endocytosis	Any process that activates or increases the frequency, rate or extent of receptor mediated endocytosis, the uptake of external materials by cells, utilizing receptors to ensure specificity of transport.
	GO:1904437	positive regulation of transferrin receptor binding	Any process that activates or increases the frequency, rate or extent of transferrin receptor binding.
	GO:0042026	protein refolding	The process carried out by a cell that restores the biological activity of an unfolded or misfolded protein, using helper proteins such as chaperones.
	GO:0050690	regulation of defense response to virus by virus	Any viral process that modulates the frequency, rate, or extent of the antiviral response of the host cell or organism.
	GO:0050776	regulation of immune response	Any process that modulates the frequency, rate or extent of the immune response, the immunological reaction of an organism to an immunogenic stimulus.
	GO:0003254	regulation of membrane depolarization	Any process that modulates the rate, frequency or extent of membrane depolarization. Membrane depolarization is the process in which membrane potential changes in the depolarizing direction from the resting potential, usually from negative to positive.
	GO:0046686	response to cadmium ion	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a cadmium (Cd) ion stimulus.
	GO:0042493	response to drug	Any process that results in a change in state or activity of a cell or an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a drug stimulus. A drug is a substance used in the diagnosis, treatment or prevention of a disease.
	GO:0002237	response to molecule of bacterial origin	Any process that results in a change in state or activity of an organism (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a stimulus by molecules of bacterial origin such as peptides derived from bacterial flagellin.
	GO:0001895	retina homeostasis	A tissue homeostatic process involved in the maintenance of an internal equilibrium within the retina of the eye, including control of cellular proliferation and death and control of metabolic function.
cellular component
	GO:0012507	ER to Golgi transport vesicle membrane	The lipid bilayer surrounding a vesicle transporting substances from the endoplasmic reticulum to the Golgi.
	GO:0005794	Golgi apparatus	A compound membranous cytoplasmic organelle of eukaryotic cells, consisting of flattened, ribosome-free vesicles arranged in a more or less regular stack. The Golgi apparatus differs from the endoplasmic reticulum in often having slightly thicker membranes, appearing in sections as a characteristic shallow semicircle so that the convex side (cis or entry face) abuts the endoplasmic reticulum, secretory vesicles emerging from the concave side (trans or exit face). In vertebrate cells there is usually one such organelle, while in invertebrates and plants, where they are known usually as dictyosomes, there may be several scattered in the cytoplasm. The Golgi apparatus processes proteins produced on the ribosomes of the rough endoplasmic reticulum; such processing includes modification of the core oligosaccharides of glycoproteins, and the sorting and packaging of proteins for transport to a variety of cellular locations. Three different regions of the Golgi are now recognized both in terms of structure and function: cis, in the vicinity of the cis face, trans, in the vicinity of the trans face, and medial, lying between the cis and trans regions.
	GO:0000139	Golgi membrane	The lipid bilayer surrounding any of the compartments of the Golgi apparatus.
	GO:1990712	HFE-transferrin receptor complex	A protein complex containing at least HFE and a transferrin receptor (either TFR1/TFRC or TFR2), proposed to play a role in the sensing of transferrin-bound Fe (Fe2-Tf) on the plasma membrane to regulate hepcidin transcription.
	GO:0042612	MHC class I protein complex	A transmembrane protein complex composed of a MHC class I alpha chain and an invariant beta2-microglobin chain, and with or without a bound peptide antigen. Class I here refers to classical class I molecules.
	GO:0005737	cytoplasm	All of the contents of a cell excluding the plasma membrane and nucleus, but including other subcellular structures.
	GO:0031905	early endosome lumen	The volume enclosed by the membrane of an early endosome.
	GO:0031901	early endosome membrane	The lipid bilayer surrounding an early endosome.
	GO:0005788	endoplasmic reticulum lumen	The volume enclosed by the membranes of the endoplasmic reticulum.
	GO:0009897	external side of plasma membrane	The leaflet of the plasma membrane that faces away from the cytoplasm and any proteins embedded or anchored in it or attached to its surface.
	GO:0070062	extracellular exosome	A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm.
	GO:0005576	extracellular region	The space external to the outermost structure of a cell. For cells without external protective or external encapsulating structures this refers to space outside of the plasma membrane. This term covers the host cell environment outside an intracellular parasite.
	GO:0005615	extracellular space	That part of a multicellular organism outside the cells proper, usually taken to be outside the plasma membranes, and occupied by fluid.
	GO:0005925	focal adhesion	Small region on the surface of a cell that anchors the cell to the extracellular matrix and that forms a point of termination of actin filaments.
	GO:0016020	membrane	A lipid bilayer along with all the proteins and protein complexes embedded in it an attached to it.
	GO:0030670	phagocytic vesicle membrane	The lipid bilayer surrounding a phagocytic vesicle.
	GO:0005886	plasma membrane	The membrane surrounding a cell that separates the cell from its external environment. It consists of a phospholipid bilayer and associated proteins.

Visualization

Interactive Views

Still Images

Databases and Analysis Tools

Databases

Analysis Tools

Related Entries

Entries Sharing at Least One Protein Chain (UniProt ID)

Related Entries Specified in the PDB File

1a1m	MHC CLASS I MOLECULE B*5301 COMPLEXED WITH PEPTIDETYPDINQML FROM GAG PROTEIN OF HIV2
1a1n	MHC CLASS I MOLECULE B*3501 COMPLEXED WITH PEPTIDE VPLRPMTYFROM THE NEF PROTEIN (75- 82) OF HIV1
1a1o	MHC CLASS I MOLECULE B5301 COMPLEXED WITH PEPTIDE LS6 (KPIVQYDNF) FROM THE MALARIA PARASITE P. FALCIPARUM
1a6z	HFE (HUMAN) HEMOCHROMATOSIS PROTEIN
1a9b	DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1a9e	DECAMER-LIKE CONFORMATION OF A NANO-PEPTIDE BOUND TO HLA-B 3501 DUE TO NONSTANDARD POSITIONING OF THE C-TERMINUS
1agb	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGRKKYKL - 3R MUTATION)
1agc	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKKYQL - 7Q MUTATION)
1agd	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKKYKL - INDEX PEPTIDE)
1age	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKKYRL - 7R MUTATION)
1agf	ANTAGONIST HIV-1 GAG PEPTIDES INDUCE STRUCTURAL CHANGES IN HLA B8 - HIV-1 GAG PEPTIDE (GGKKRYKL - 5R MUTATION)
1akj	COMPLEX OF THE HUMAN MHC CLASS I GLYCOPROTEIN HLA-A2 ANDTHE T CELL CORECEPTOR CD8
1ao7	COMPLEX BETWEEN HUMAN T-CELL RECEPTOR, VIRAL PEPTIDE (TAX), AND HLA-A 0201
1aqd	HLA-DR1 (DRA, DRB1 0101) HUMAN CLASS II HISTOCOMPATIBILITYPROTEIN (EXTRACELLULAR DOMAIN) COMPLEXED WITH ENDOGENOUSPEPTIDE
1b0g	CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH BETA 2- MICROGLOBULIN AND HUMAN PEPTIDE P1049
1b0r	CRYSTAL STRUCTURE OF HLA-A0201 COMPLEXED WITH A PEPTIDE WITH THE CARBOXYL-TERMINAL GROUP SUBSTITUTED BY A METHYL GROUP
1bd2	COMPLEX BETWEEN HUMAN T-CELL RECEPTOR B7, VIRAL PEPTIDE (TAX) AND MHC CLASS I MOLECULE HLA-A 0201
1c16	CRYSTAL STRUCTURE ANALYSIS OF THE GAMMA/ DELTA T CELL LIGAND T22
1ce6	MHC CLASS I H-2DB COMPLEXED WITH A SENDAI VIRUSNUCLEOPROTEIN PEPTIDE
1cg9	COMPLEX RECOGNITION OF THE SUPERTYPIC BW6- DETERMINANT ONHLA-B AND-C MOLECULES BY THE MONOCLONAL ANTIBODY SFR8-B6
1de4	HEMOCHROMATOSIS PROTEIN HFE COMPLEXED WITH TRANSFERRINRECEPTOR
1duy	CRYSTAL STRUCTURE OF HLA-A0201/OCTAMERIC TAX PEPTIDE COMPLEX
1duz	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) INCOMPLEX WITH A NONAMERIC PEPTIDE FROM HTLV-1 TAX PROTEIN
1e27	NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM1 (LPPVVAKEI)
1e28	NONSTANDARD PEPTIDE BINDING OF HLA-B*5101 COMPLEXED WITH HIV IMMUNODOMINANT EPITOPE KM2 (TAFTIPSI)
1eey	CRYSTAL STRUCTURE DETERMINATION OF HLA A2 COMPLEXED TOPEPTIDE GP2 WITH THE SUBSTITUTION (I2L/V5L/L9V)
1eez	CRYSTAL STRUCTURE DETERMINATION OF HLA-A2.1 COMPLEXED TOGP2 PEPTIDE VARIANT(I2L/V5L)
1efx	STRUCTURE OF A COMPLEX BETWEEN THE HUMAN NATURAL KILLER CELL RECEPTOR KIR2DL2 AND A CLASS I MHC LIGAND HLA-CW3
1exu	CRYSTAL STRUCTURE OF THE HUMAN MHC-RELATED FC RECEPTOR
1gzp	CD1B IN COMPLEX WITH GM2 GANGLIOSIDE
1gzq	CD1B IN COMPLEX WITH PHOPHATIDYLINOSITOL
1hhg
1hhh
1hhi
1hhj	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEX WITH A NONAMERIC PEPTIDE FROM HIV-1 REVERSE TRANSCRIPTASE (RESIDUES 309-317)
1hhk
1hla	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2 ( HLA-A2, HUMAN LEUCOCYTE ANTIGEN)
1hsa	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA- B(ASTERISK)2705
1hsb	CLASS I HISTOCOMPATIBILITY ANTIGEN AW68.1 ( LEUCOCYTE ANTIGEN)
1i1f	CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH BETA 2- MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1i1y	CRYSTAL STRUCTURE OF HUMAN CLASS I MHC ( HLA-A2.1) COMPLEXED WITH BETA 2- MICROGLOBULIN AND HIV-RT VARIANT PEPTIDE I1Y
1i4f	CRYSTAL STRUCTURE OF HLA-A*0201/MAGE-A4- PEPTIDE COMPLEX
1i7r	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1058
1i7t	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-5V
1i7u	CRYSTAL STRUCTURE OF CLASS I MHC A2 IN COMPLEX WITH PEPTIDEP1049-6V
1im3	CRYSTAL STRUCTURE OF THE HUMAN CYTOMEGALOVIRUS PROTEIN US2BOUND TO THE MHC CLASS I MOLECULE HLA-A2/TAX
1im9	CRYSTAL STRUCTURE OF THE HUMAN NATURAL KILLER CELLINHIBITORY RECEPTOR KIR2DL1 BOUND TO ITS MHC LIGAND HLA-CW4
1jf1	CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ADECAMERIC ALTERED PEPTIDE LIGAND FROM THE MART-1/MELAN-A
1jgd	HLA-B*2709 BOUND TO DECA-PEPTIDE S10R
1jge	HLA-B*2705 BOUND TO NONA-PEPTIDE M9
1jht	CRYSTAL STRUCTURE OF HLA-A2*0201 IN COMPLEX WITH ANONAMERIC ALTERED PEPTIDE LIGAND (ALGIGILTV) FROM THE MART-1/MELAN-A.
1jnj	NMR SOLUTION STRUCTURE OF THE HUMAN BETA2- MICROGLOBULIN
1k5n	HLA-B*2709 BOUND TO NONA-PEPTIDE M9
1kpr	THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEXMOLECULE HLA-E
1ktl	THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEXMOLECULE HLA-E
1lds	CRYSTAL STRUCTURE OF MONOMERIC HUMAN BETA-2 -MICROGLOBULIN
1lp9	XENOREACTIVE COMPLEX AHIII 12.2 TCR BOUND TO P1049/HLA-A2.1
1m05	HLA B8 IN COMPLEX WITH AN EPSTEIN BARR VIRUS DETERMINANT
1m6o	CRYSTAL STRUCTURE OF HLA B4402 IN COMPLEX WITH HLADPA0201 PEPTIDE
1mhe	THE HUMAN NON-CLASSICAL MAJOR HISTOCOMPATIBILITY COMPLEX MOLECULE HLA-E
1mi5	THE CRYSTAL STRUCTURE OF LC13 TCR IN COMPLEX WITH HLAB8-EBVPEPTIDE COMPLEX
1n2r	A NATURAL SELECTED DIMORPHISM IN HLA B*44 ALTERS SELF,PEPTIDE REPORTOIRE AND T CELL RECOGNITION.
1of2	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VPAC1) PEPTIDE (RESIDUES 400-408 )
1oga	A STRUCTURAL BASIS FOR IMMUNODOMINANT HUMAN T-CELL RECEPTOR RECOGNITION.
1ogt	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE VASOACTIVE INTESTINAL PEPTIDE TYPE 1 RECEPTOR (VPAC1) PEPTIDE (RESIDUES 400-408 )
1onq	CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SULFATIDE
1p7q	CRYSTAL STRUCTURE OF HLA-A2 BOUND TO LIR- 1, A HOST ANDVIRAL MHC RECEPTOR
1py4	BETA2 MICROGLOBULIN MUTANT H31Y DISPLAYS HINTS FOR AMYLOIDFORMATIONS
1q94	STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANTNONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THEPRESENCE OF A MIDDLE ANCHOR RESIDUE
1qew	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201)COMPLEX WITH A NONAMERIC PEPTIDE FROM MELANOMA-ASSOCIATEDANTIGEN 3 (RESIDUES 271-279)
1qlf	MHC CLASS I H-2DB COMPLEXED WITH GLYCOPEPTIDE K3G
1qqd	CRYSTAL STRUCTURE OF HLA-CW4, A LIGAND FOR THE KIR2D NATURAL KILLER CELL INHIBITORY RECEPTOR
1qr1	POOR BINDING OF A HER-2/NEU EPITOPE (GP2 ) TO HLA-A2.1 IS DUE TO A LACK OF INTERACTIONS IN THE CENTER OF THE PEPTIDE
1qrn	CRYSTAL STRUCTURE OF HUMAN A6 TCR COMPLEXED WITH HLA-A2 BOUND TO ALTERED HTLV-1 TAX PEPTIDE P6A
1qse	STRUCTURE OF HUMAN A6-TCR BOUND TO HLA- A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE V7R
1qsf	STRUCTURE OF A6-TCR BOUND TO HLA-A2 COMPLEXED WITH ALTERED HTLV-1 TAX PEPTIDE Y8A
1qvo	STRUCTURES OF HLA-A*1101 IN COMPLEX WITH IMMUNODOMINANTNONAMER AND DECAMER HIV-1 EPITOPES CLEARLY REVEAL THEPRESENCE OF A MIDDLE ANCHOR RESIDUE
1r3h	CRYSTAL STRUCTURE OF T10
1s8d	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3A
1s9w	CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE, SLLMWITQC,IN COMPLEX WITH HLA-A2
1s9x	CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE,SLLMWITQA, IN COMPLEX WITH HLA-A2
1s9y	CRYSTAL STRUCTURE ANALYSIS OF NY-ESO-1 EPITOPE ANALOGUE,SLLMWITQS, IN COMPLEX WITH HLA-A2
1sys	CRYSTAL STRUCTURE OF HLA, B*4403, AND PEPTIDE EEPTVIKKY
1syv	HLA-B*4405 COMPLEXED TO THE DOMINANT SELF LIGAND EEFGRAYGF
1t1w	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-3F6I8V
1t1x	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-4L
1t1y	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-5V
1t1z	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6A
1t20	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9-6I
1t21	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9, MONOCLINICCRYSTAL
1t22	STRUCTURAL BASIS FOR DEGENERATE RECOGNITION OF HIV PEPTIDEVARIANTS BY CYTOTOXIC LYMPHOCYTE, VARIANT SL9,ORTHORHOMBIC CRYSTAL
1tmc	TRUNCATED HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN HLA-AW68 COMPLEXED WITH A DECAMERIC PEPTIDE (EVAPPEYHRK)
1tvb	CRYSTAL STRUCTURE OF MELANOMA ANTIGEN GP100( 209-217) BOUNDTO HUMAN CLASS I MHC HLA- A2
1tvh	CRYSTAL STRUCTURE OF MODIFIED MELANOMA ANTIGEN GP100(209-T2M) BOUND TO HUMAN CLASS I MHC HLA-A2
1uqs	THE CRYSTAL STRUCTURE OF HUMAN CD1B WITH A BOUND BACTERIAL GLYCOLIPID
1ur7	MOLECULAR REFINEMENT OF ANTI-HLA-A2 USING LIGHT CHAIN SHUFFLING: A STRUCTURAL MODEL FOR HLA ANTIBODY BINDING
1uxs	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2)OF EPSTEIN-BARR VIRUS
1uxw	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE LATENT MEMBRANE PROTEIN 2 PEPTIDE (LMP2) OF EPSTEIN-BARR VIRUS
1vgk	THE CRYSTAL STRUCTURE OF CLASS I MAJOR HISTOCOMPATIBILITYCOMPLEX, H-2KD AT 2.0 A RESOLUTION
1w0v	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF- RESPONSE FACTOR 1
1w0w	CRYSTAL STRUCTURE OF HLA-B*2709 COMPLEXED WITH THE SELF-PEPTIDE TIS FROM EGF- RESPONSE FACTOR 1
1w72	CRYSTAL STRUCTURE OF HLA-A1:MAGE-A1 IN COMPLEX WITH FAB-HYB3
1x7q	CRYSTAL STRUCTURE OF HLA-A*1101 WITH SARS NUCLEOCAPSIDPEPTIDE
1xh3	CONFORMATIONAL RESTRAINTS AND FLEXIBILITY OF 14-MERICPEPTIDES IN COMPLEX WITH HLA-B* 3501
1xr8	CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDESFROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1xr9	CRYSTAL STRUCTURES OF HLA-B*1501 IN COMPLEX WITH PEPTIDESFROM HUMAN UBCH6 AND EPSTEIN-BARR VIRUS EBNA-3
1xz0	CRYSTAL STRUCTURE OF CD1A IN COMPLEX WITH A SYNTHETICMYCOBACTIN LIPOPEPTIDE
1ydp	1.9A CRYSTAL STRUCTURE OF HLA-G
1ypz	IMMUNE RECEPTOR
1zs8	CRYSTAL STRUCTURE OF THE MURINE MHC CLASS IB MOLECULE M10.5
1zsd	CRYSTAL STRUCTURE OF HLA-B*3501 PRESENTING AN 11-MER EBVANTIGEN EPLPQGQLTAY
1zt4	THE CRYSTAL STRUCTURE OF HUMAN CD1D WITH AND WITHOUT ALPHA-GALACTOSYLCERAMIDE
2a83	CRYSTAL STRUCTURE OF HLA-B*2705 COMPLEXED WITH THE GLUCAGONRECEPTOR (GR) PEPTIDE ( RESIDUES 412-420)
2ak4	CRYSTAL STRUCTURE OF SB27 TCR IN COMPLEX WITH HLA-B*3508-13MER PEPTIDE
2av1	CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMANCLASS I MHC HLA-A2 WITH THE E63Q AND K66A MUTATIONS IN THEHEAVY CHAIN.
2av7	CRYSTAL STRUCTURE OF HTLV-1 TAX PEPTIDE BOUND TO HUMANCLASS I MHC HLA-A2 WITH THE K66A MUTATION IN THE HEAVYCHAIN.
2axf	THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE ISCONTROLLED BY ITS MHC-BOUND CONFORMATION
2axg	THE IMMUNOGENICITY OF A VIRAL CYTOTOXIC T CELL EPITOPE ISCONTROLLED BY ITS MHC-BOUND CONFORMATION
2bck	CRYSTAL STRUCTURE OF HLA-A*2402 COMPLEXED WITH A TELOMERASEPEPTIDE
2bnq	STRUCTURAL AND KINETIC BASIS FOR HIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2bnr	STRUCTURAL AND KINETIC BASIS FOR HIGHTENED IMMUNOGENICITY OF T CELL VACCINES
2bsr	CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2bss	CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2bst	CRYSTAL STRUCTURES AND KIR3DL1 RECOGNITION OF THREE IMMUNODOMINANT VIRAL PEPTIDES COMPLEXED TO HLA-B2705
2bsu	T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
2bsv	T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
2bvq	STRUCTURES OF THREE HIV-1 HLA-B5703- PEPTIDE COMPLEXES AND IDENTIFICATION OF RELATED HLAS POTENTIALLY ASSOCIATED WITH LONG -TERM NON-PROGRESSION
2c7u	CONFLICTING SELECTIVE FORCES AFFECT CD8 T- CELL RECEPTOR CONTACT SITES IN AN HLA-A2 IMMUNODOMINANT HIV EPITOPE.
2cii	THE CRYSTAL STRUCTURE OF H-2DB COMPLEXED WITH A PARTIAL PEPTIDE EPITOPE SUGGESTS AN MHC CLASS I ASSEMBLY-INTERMEDIATE
2cik	INSIGHTS INTO CROSSREACTIVITY IN HUMAN ALLORECOGNITION: THE STRUCTURE OF HLA-B35011 PRESENTING AN EPITOPE DERIVED FROM CYTOCHROME P450.
2clr	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN (HLA -A 0201) COMPLEXED WITH A DECAMERIC PEPTIDE FROM CALRETICULIN
2d31	CRYSTAL STRUCTURE OF DISULFIDE-LINKED HLA-G DIMER
2esv	STRUCTURE OF THE HLA-E-VMAPRTLIL/KK50.4 TCR COMPLEX
2f74	MURINE MHC CLASS I H-2DB IN COMPLEX WITH HUMAN B2-MICROGLOBULIN AND LCMV-DERIVED IMMUNODMINANT PEPTIDE GP33
2f8o	A NATIVE TO AMYLOIDOGENIC TRANSITION REGULATED BY ABACKBONE TRIGGER
2gj6	THE COMPLEX BETWEEN TCR A6 AND HUMAN CLASS I MHC HLA-A2WITH THE MODIFIED HTLV-1 TAX (Y5K-4-[3-INDOLYL]-BUTYRICACID) PEPTIDE
2h26	HUMAN CD1B IN COMPLEX WITH ENDOGENOUS PHOSPHATIDYLCHOLINEAND SPACER
2hjk	CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2hjl	CRYSTAL STRUCTURE OF HLA-B5703 AND HIV-1 PEPTIDE
2hla	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN AW 68.1 (HLA-AW 68.1, HUMAN LEUCOCYTE ANTIGEN)
2jcc	AH3 RECOGNITION OF MUTANT HLA-A2 W167A
2uwe	LARGE CDR3A LOOP ALTERATION AS A FUNCTION OF MHC MUTATION
2v2w	T CELL CROSS-REACTIVITY AND CONFORMATIONAL CHANGES DURING TCR ENGAGEMENT
3hla	HUMAN CLASS I HISTOCOMPATIBILITY ANTIGEN A2. 1 (HLA-A2.1 HUMAN LEUCOCYTE ANTIGEN)

Description

Compounds

Structural Features

Chains, Units

Ligands, Modified Residues, Ions (0, 0)

Sites (0, 0)

SS Bonds (6, 6)

Cis Peptide Bonds (4, 4)

Sequence-Structure Mapping

SAPs(SNPs)/Variants (24, 48)